CRVS
Corvus Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.06B
P/E Ratio
—
EPS
$-0.55
Beta
0.94
52W High
$26.95
52W Low
$3.49
50-Day MA
$14.76
200-Day MA
$11.24
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company is headquartered in Burlingame, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-47.81M |
| Operating Margin | 0.00% |
| Return on Equity | -30.50% |
| Return on Assets | -19.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.86 |
| Price-to-Book | 4.41 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.36 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $84.09M |
| Float | $72.79M |
| % Insiders | 3.51% |
| % Institutions | 85.05% |
Historical Volatility
HV 10-Day
108.69%
HV 20-Day
91.24%
HV 30-Day
95.41%
HV 60-Day
83.18%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($33.33 target)
1
Strong Buy6
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026